Market closed
Madrigal Pharmaceuticals/$MDGL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Ticker
$MDGL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
376
Website
MDGL Metrics
BasicAdvanced
$6.4B
Market cap
-
P/E ratio
-$25.02
EPS
-0.40
Beta
-
Dividend rate
Price and volume
Market cap
$6.4B
Beta
-0.4
52-week high
$343.00
52-week low
$168.25
Average daily volume
388K
Financial strength
Current ratio
5.981
Quick ratio
5.814
Long term debt to equity
15.217
Total debt to equity
15.33
Interest coverage (TTM)
-36.19%
Management effectiveness
Return on assets (TTM)
-52.25%
Return on equity (TTM)
-129.76%
Valuation
Price to revenue (TTM)
79.194
Price to book
8.23
Price to tangible book (TTM)
8.23
Price to free cash flow (TTM)
-13.878
Growth
Earnings per share change (TTM)
30.04%
3-year earnings per share growth (CAGR)
19.52%
What the Analysts think about MDGL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Madrigal Pharmaceuticals stock.
MDGL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MDGL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MDGL News
AllArticlesVideos
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Seeking Alpha·2 months ago
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Madrigal Pharmaceuticals stock?
Madrigal Pharmaceuticals (MDGL) has a market cap of $6.4B as of December 21, 2024.
What is the P/E ratio for Madrigal Pharmaceuticals stock?
The price to earnings (P/E) ratio for Madrigal Pharmaceuticals (MDGL) stock is 0 as of December 21, 2024.
Does Madrigal Pharmaceuticals stock pay dividends?
No, Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Madrigal Pharmaceuticals dividend payment date?
Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) has a beta rating of -0.4. This means that it has an inverse relation to market volatility.